Table 4. Additional treatment for recurrent tumor at a gastric site other than the primary resection area.
| Variable | Primary lesion | P-value | |
|---|---|---|---|
| Differentiated cancer | Undifferentiated cancer | ||
| Patient, n | 1,447 | 113 | |
| Synchronous or metachronous tumor, n | 128 | 3 | |
| Additional treatment for synchronous or metachronous tumor, n (%)a | 113 (7.8) | 2 (1.8) | 0.018 |
| Surgery | 12 (0.8) | 0 (0.0) | >0.999 |
| Endoscopic resection | 89 (6.2) | 2 (1.8) | 0.056 |
| APC ablation | 11 (0.8) | 0 (0.0) | >0.999 |
| Palliative chemotherapy | 1 (0.1) | 0 (0.0) | >0.999 |
| Observation for synchronous or metachronous lesion, n (%) | 15 (1.0) | 1 (0.9) | >0.999 |
aThe proportion of variables was calculated from the number of enrolled patients.
APC, argon plasma coagulation